SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
14 sept. 2022 11h22 HE | Sermonix Pharmaceuticals Inc.
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s...
QMI-Logo-Long-1000px.jpg
Medical Image Analysis Software Market Size, Share, Trends Analysis 2030; Quince Market Insights
14 sept. 2022 10h00 HE | Quince Market Insights
Pune, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Global Medical Image Analysis Software Market includes a global opportunity analysis and industry forecasts for the period 2023-2032. The global market...
new_logo.png
North America Contract Research Organization Market Size to exceed $34.2 Bn by 2028, says Graphical Research
14 sept. 2022 08h00 HE | Graphical Research
Pune, India, Sept. 14, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America contract research organization market is forecast to register...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
13 sept. 2022 09h00 HE | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Onconova Logo BLUE.jpg
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022
12 sept. 2022 08h00 HE | Onconova Therapeutics, Inc.
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3...
logo.png
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
12 sept. 2022 08h00 HE | Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
Nouveau Logo communiqué de presse.JPG
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
12 sept. 2022 07h30 HE | Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
Nouveau Logo communiqué de presse.JPG
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
12 sept. 2022 07h30 HE | Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
10 sept. 2022 04h00 HE | Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
POINT-Logo-Colour (blue).png
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
10 sept. 2022 03h05 HE | POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...